Your best source on business and economy news from Rhode Island
Provided by AGP
enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ: ENGN). The investigation focuses on enGene’s executive officers and whether investor losses may be recovered under federal securities laws.
What if I purchased enGene securities?
If you purchased enGene securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.
Background of the investigation
On May 7, 2026, enGene announced updated interim results from the pivotal cohort of its ongoing Phase 2 LEGEND trial of detalimogene voraplasmid in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
Among other things, enGene disclosed that patients treated with detalimogene achieved a 54% complete response rate at any time and a 43% complete response rate at six months.
However, enGene also disclosed that the Kaplan-Meier estimate of 12-month duration of response was 25%. In addition, the Company stated that “durability outcomes to date are not what we hoped.”
enGene further disclosed that, among the 32 patients who had their first disease assessment after the Company’s last data analysis, complete response rates were lower than previously reported results. For those patients, the complete response rate at any time was 39%, and the complete response rate at six months was 32%.
Following this disclosure, enGene’s stock price declined sharply, damaging investors.
In light of this disclosure, Johnson Fistel is investigating whether enGene complied with the federal securities laws. If you suffered losses from your investment in enGene stock, contact Johnson Fistel.
About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.
Achievements
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | jimb@johnsonfistel.com |
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
